Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Research & Development (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Research & Development for 7 consecutive years, with $99.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 2.14% to $99.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $409.6 million through Dec 2025, up 11.44% year-over-year, with the annual reading at $409.6 million for FY2025, 11.44% up from the prior year.
  • Research & Development for Q4 2025 was $99.3 million at Beam Therapeutics, down from $109.8 million in the prior quarter.
  • The five-year high for Research & Development was $190.1 million in Q1 2021, with the low at $45.6 million in Q2 2021.
  • Average Research & Development over 5 years is $95.7 million, with a median of $97.2 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 782.2% in 2021, then plummeted 65.59% in 2022.
  • Over 5 years, Research & Development stood at $96.8 million in 2021, then decreased by 10.79% to $86.3 million in 2022, then skyrocketed by 62.24% to $140.1 million in 2023, then decreased by 27.58% to $101.4 million in 2024, then fell by 2.14% to $99.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $99.3 million, $109.8 million, and $101.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.